| Revenue Growth | Diagnostic revenue $0.7M; gross charges $1.55M from 222 tests in Q3. |
|---|---|
| Mgmt Confidence | Confident in breaking Phase 1 radiation ceilings without dose-limiting toxicities. |
| Demand Visibility | 34 institutions in onboarding backlog; 190 million total covered lives reached. |
| Order Book | 512 tumor cell tests year-to-date; 26 institutions and 45 providers ordering. |
| Margin Trends | Cost of revenue $0.9M against $0.7M revenue; diagnostic burn $10M annually. |
| Op. Leverage | Expect testing and collections to materially offset cash burn by H2 2027. |
| Pricing Power | Aetna national agreement includes contracted rates for cell enumeration and profiling. |
| Vol vs Price | Growth driven by new accounts, patient monitoring, and expanded test menu. |
| Segment Growth | Diagnostics scaling; Therapeutics (Rheobic) in Phase 2 with mid-2027 data expected. |
| New Clients | Added Aetna national contract; 100 signed access agreements awaiting conversion. |
| Capex & Debt | Ended September with $4.9M cash; accessed $20M royalty/financing facility. |
| Regulatory | Medicare reimbursement tracking for H1 2027; FDA aligned on dose optimization. |
| Commentary | Strategic focus on 'compounding' adoption, monitoring frequency, and menu expansion per specimen. |
| New Launches | Launched CSF molecular profile October 12; breast cancer assays launching 2027. |
Growth
Diagnostic revenue was $0.7M; October test volume grew 15% over Q3 average.
Outlook
Targeting $10M-$12.5M annualized gross billing run rate exit 2026; doubling in 2027.
Risks
Management pivoted to gross billings instead of revenue guidance due to lack of collection history.
The company's earnings call, NASDAQ: CNSY, and its 8-K filed with the SEC. Summary written with AI assistance from the call.
Earnings call webcast ↗ Watch on YouTube ↗
Cerenome, Inc.: key numbers
- Share price
- $0.7148Close, Nov 16
- Market cap
- $6.99M
- Shares outstanding
- 9.78MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Cerenome, Inc.
All →Cerenome Clinical Trial Data
Cerenome reported interim data from its Phase 1 ReSPECT-LM study evaluating repeat dosing of REYOBIQ in patients with leptomeningeal metastases. The data showed no dose-limiting toxicities in the first 10 patients and indicated consistent radiation delivery across repeat administrations, with early disease control signals showing no progression in evaluable patients at the six-month landmark.
- Counterparty
- Society for Neuro-Oncology
Cerenome Q3 2026 Results: Net Loss of $8.66M, Loss Widens
Cerenome, Inc. reported a net loss of $24.6 million for the nine months ended September 30, 2026, compared to a $16.7 million loss in the prior year period. While the company introduced diagnostic revenue of $0.7 million, total revenue decreased due to lower grant revenue, and operating expenses nearly doubled to $25.8 million.
- Key figure
- Net loss $8.66M
Cerenome Financial Results
Cerenome (formerly Plus Therapeutics) reported Q3 2026 financial results, highlighting its first quarter of CNSide diagnostic revenue totaling $0.7 million. The company expanded its payer coverage to approximately 190 million lives and completed enrollment in its Phase 2 glioblastoma trial. Additionally, the company rebranded from Plus Therapeutics to Cerenome during the quarter.
- Term
- Q3 2026
“Recognition of our first quarter of CNSide® diagnostic revenue and commercial payments beginning in October is a tremendous landmark. Furthermore, our payer universe continues to expand with now about 80% of U.S. private payers representing approximately 190 million covered lives. Most recently, with Aetna coverage, it gives physicians an in-network option for both tumor cell enumeration and molecular profiling. In parallel, our growing commercial team is focused on helping more cancer centers use our test in patient care. In therapeutics, we materially advanced our two key programs by completing enrollment in our Phase 2 trial in adults with recurrent glioblastoma, opening up higher dose cohorts in the repeat dosing of REYOBIQ™ in patients with leptomeningeal metastases and reporting interim data in that trial.”
Marc H. Hedrick, M.D., Cerenome’s President and Chief Executive Officer
Cerenome Executive Compensation
Cerenome, Inc. appointed Ronald A. Andrews as its new Chief Business Officer, effective November 9, 2026. Mr. Andrews, who already serves on the company's board, entered into an employment agreement providing for an annual base salary of $344,955, a 43% target bonus, and an option to purchase 92,858 shares of common stock.
- Counterparty
- Ronald A. Andrews
Cerenome Investor Presentation
Cerenome, Inc. (formerly Plus Therapeutics, Inc.) filed an updated corporate presentation as of September 30, 2026, for use in meetings with investors and analysts. The presentation covers the company's clinical trials, strategic collaborations, and the development of its CNSide platform for genomic testing.